Form 4: Enliven Therapeutics Director Richard A. Heyman Reports Stock Sales

Richard A. Heyman, a director at Enliven Therapeutics, reported selling shares of common stock on July 31, 2024, under a pre-arranged trading plan.

Summary

• On July 31, 2024, Richard A. Heyman, a director of Enliven Therapeutics, sold 1,702 shares of common stock at a weighted average price of $27.5059.
• He also sold 649 shares at a weighted average price of $27.50.
• These sales were executed under Rule 10b5-1 trading plans adopted on July 17, 2023.
• Following these transactions, Heyman directly owns 131,643 shares and indirectly owns 27,918 shares through RAHD Capital LLC and 37,407 shares through the Richard A. Heyman and Anne E. Daigle Trust.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock sales by a company director under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when a company insider, such as a director, buys or sells shares of their company's stock. It provides transparency to the market regarding insider transactions.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders, ensuring compliance with SEC regulations.
• Similar filings are made by executives and directors at comparable companies in the biotechnology sector, such as Amgen (AMGN) and Gilead Sciences (GILD), whenever they trade their company's stock.

Stakeholder Impact

• The stock sales may have a minor impact on shareholders, as insider transactions are often scrutinized by investors.
• The sales were conducted under a pre-arranged trading plan, which mitigates concerns about opportunistic trading based on inside information.

Key Dates